|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
Thursday
"Schering's Betaseron drug has received approval in Europe as a first-line treatment for the earliest stages of MS:
Schering, which rival drugmaker Bayer (BAYG.DE: Quote, Profile, Research) is trying to acquire, said that results of a trial using Betaseron showed that the drug taken in the early phase of the disease could cut risk of MS by 50 percent. Betaseron is Schering's top drug and brought in 232 million euros ($299 million) in sales in the first quarter, an increase of 23 percent from a year earlier. It is currently used to treat relapsing remitting MS and secondary progressive MS....." |